Screening for Dementia: Summary of the Evidence (continued)

You Are Here: AHRQ Home > Clinical Information > U.S. Preventive Services Task Force (USPSTF) > Screening: Dementia > Summary of the Evidence

Acknowledgments

Dr. Boustani would like to thank the Program on Aging, John A. Hartford Foundation, New York City and the American Federation for Aging Research for their career development support. We thank our liaisons from the U.S. Preventive Services Task Force—Cynthia Mulrow, M.D., M.Sc., of the University of Texas Health Sciences Center, San Antonio, TX; and Albert Siu, M.D., M.S.P.H., of Mount Sinai Medical Center, New York, NY—for their assistance on the full systematic evidence review from which this article has been developed. We acknowledge David Atkins, M.D., M.P.H., Director, AHRQ Clinical Prevention Program, for his advice and counsel throughout this project. Finally, we thank our RTI-UNC EPC colleagues Sonya Sutton, B.S.P.H., and Loraine Monroe (both of RTI) and Carol Krasnov and Audrina Bunton (both of the University of North Carolina) for their assistance in this project and production of this article.

This evidence report was developed by the RTI-University of North Carolina Evidence-based Practice Center under contract to the Agency for Healthcare Research and Quality (Contract No. 290-97-0011), Rockville, MD. Staff of the funding agency and members of the USPSTF contributed to the study design, reviewed draft and final manuscripts, and made editing suggestions.

Return to Contents

References

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC; 1994.

2. Boustani M, Peterson B, Hanson L, et al. Screening for Dementia. A Systematic Evidence Review. Available at http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat3.chapter.28271. Rockville, MD: Agency for Healthcare Research and Quality; 2002.

3. Lautenschlager N, Cupples L, Rao V, et al. Risk of dementia among relatives of Alzheimer's disease patients in the MIRAGE study: What is in store for the oldest old? Neurology 1996;46:641-50.

4. Blacker D, Tanzi R. The genetics of Alzheimer disease: current status and future prospects. Arch Neurol 1998;55:294-96.

5. Lai F, Williams R. A prospective study of Alzheimer disease in Down syndrome. Arch Neurol 1989;46:849-53.

6. Longstreth W Jr, Bernick C, Manolio T, Bryan N, Jungreis C, Price T. Lacunar infarcts defined by magnetic resonance imaging of 3660 elderly people: the Cardiovascular Health Study. Arch Neurol 1998;55:1217-25.

7. Hofman A, Ott A, Breteler M, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997;349:151-54.

8. U.S. Office of Technology Assessment. Losing a million minds: confronting the tragedy of AD and other dementias. Washington, DC: US Government Printing Office; 1987.

9. Evans D, Funkenstein H, Albert M, et al. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA 1989;262:2551-56.

10. Evans D, Smith L, Scherr P, Albert M, Funkenstein H, Hebert L. Risk of death from Alzheimer's disease in a community population of older persons. Am J Epidemiol 1991;134:403-12.

11. U.S. General Accounting Office. Alzheimer's Disease: Estimates of prevalence in the United States. Washington, DC: U.S. General Accounting Office; 1998. Publication HEHS 98-16.

12. Patterson C , Gauthier S, Bergman H, et al. The recognition, assessment and management of dementing disorders: conclusions from the Canadian Consensus Conference on Dementia. Can Med Assoc J 1999;160(Suppl 12):S1-S15.

13. Canadian study of health and aging: study methods and prevalence of dementia. Can Med Assoc J 1994;150:899-913.

14) Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998;88:1337-42.

15. Brodaty H, Clarke J, Ganguli M, et al. Screening for cognitive impairment in general practice: toward a consensus. Alzheimer Dis Assoc Disord 1998;12:1-13.

16. Ernst RL, Hay JW. The US economic and social costs of Alzheimer's disease revisited. Am J Public Health 1994;84:1261-64.

17. Dunkin J, Anderson-Hanley C. Dementia caregiver burden: a review of the literature and guidelines for assessment and intervention. Neurology 1998;51(Suppl 1):S53-S60.

18. Grafstrom M, Fratiglioni L, Sandman P, Winblad B. Health and social consequences for relatives of demented and non-demented elderly. A population-based study. J Clin Epidemiol 1992;45:861-70.

19. Schulz R, O'Brien A, Bookwala J, Fleissner K. Psychiatric and physical morbidity effects of dementia caregiving: prevalence, correlates, and causes. Gerontologist 1995;35:771-91.

20. Hoyert DL, Kochanek KD, Murphy SL. Deaths: final data for 1997. Natl Vital Stat Rep 1999;47:1-104.

21. Gold DP, Reis MF, Markiewicz D, Andres D. When home caregiving ends: a longitudinal study of outcomes for caregivers of relatives with dementia. J Am Geriatr Soc 1995;43:10-16.

22. Arno PS, Levine C, Memmott MM. The economic value of informal caregiving. Health Aff (Millwood) 1999;18:182-8.

23. O'Connor D, Pollitt P, Hyde J, Brook C, Reiss B, Roth M. Do general practitioners miss dementia in elderly patients? Br Med J 1988;297:1107-10.

24. Lagaay A, van der Meij J, Hijmans W. Validation of medical history taking as part of a population based survey in subjects aged 85 and over. Br Med J 1992; 304:1091-92.

25. Cooper B, Bickel H, Schaufele M. Early development and progression of dementing illness in the elderly: a general-practice based study. Psycholog Med 1996;26:411-19.

26. Olafsdottir M, Skoog I, Marcusson J. Detection of dementia in primary care: the Linkoping study. Dement Geriatr Cogn Disord 2000;11:223-29.

27. Valcour V, Masaki K, Curb J, Blanchette P. The detection of dementia in the primary care setting. Arch Intern Med 2000;160:2964-68.

28. United States Preventive Services Task Force. Guide to Clinical Preventive Services, Second Edition. Washington, DC: Office of Disease Prevention and Health Promotion; 1996:531-40.

29. Petersen R, Stevens J, Ganguli M, Tangalos E, Cummings J, DeKosky S. Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1133-42.

30. Patterson CJ, Gass DA. Screening for cognitive impairment and dementia in the elderly. Can J Neurol Sci 2001;28(Suppl 1):S42-S51.

31. Harris R, Helfand M, Woolf S, et al. Current methods of the U.S. Preventive Services Task Force: A review of the process. Am J Prev Med 2001;2:21-35.

32. Eefsting J, Boersma F, Van den Brink W, Van Tilburg W. Differences in prevalence of dementia based on community survey and general practitioner recognition. Psycholog Med 1996;26:1223-30.

33. Sternberg SA, Wolfson C, Baumgarten M. Undetected dementia in community-dwelling older people: the Canadian Study of Health and Aging. J Am Geriatr Soc 2000;48:1430-34.

34. Ross GW, Abbott RD, Petrovitch H, et al. Frequency and characteristics of silent dementia among elderly Japanese-American men. The Honolulu-Asia Aging Study. JAMA 1997;277:800-5.

35. Erkinjuntti T, Ostbye T, Steenhuis R, Hachinski V. The effect of different diagnostic criteria on the prevalence of dementia. N Engl J Med 1997;337:1667-74.

36. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1143-53.

37. Costa PT Jr , Williams T, Somerfield M, et. al. Early identification of Alzheimer's disease and related dementias. Clinical Practice Guideline, Quick Reference Guide for Clinicians, No. 19. Rockville, MD: AHCPR Publication No. 97-0703; 1996: 1-28.

38. Wilder D, Cross P, Chen J, et al. Operating characteristics of brief screens for dementia in a multicultural population. Am J Geriatric Psychiatry 1995;3:96-107.

39. Jitapunkul S, Lailert C, Worakul P, Srikiatkhachorn A, et al. Chula Mental Test: A screening test for elderly people in less developed countries. Int J Geriatr Psychiatry 1996;11:714-20.

40. McDowell I, Kristjansson B, Hill GB, Hebert R. Community screening for dementia: the Mini Mental State Exam (MMSE) and Modified Mini-Mental State Exam (3MS) compared. J Clin Epidemiol 1997;50:377-83.

41. Lindeboom J , Launer LJ, Schmand BA, Hooyer C, Jonker C. Effects of adjustment on the case-finding potential of cognitive tests. J Clin Epidemiol 1996;49:691-95.

42. Law S, Wolfson C. Validation of a French version of an informant-based questionnaire as a screening test for Alzheimer's disease. Br J Psychiatry 1995;167:541-44.

43. Braekhus A, Laake K, Engedal K. A low, 'normal' score on the Mini-Mental State Examination predicts development of dementia after three years. J Am Geriatr Soc 1995;43:656-61.

44. Heun R, Papassotiropoulos A, Jennssen F. The validity of psychometric instruments for detection of dementia in the elderly general population. Int J Geriatr Psychiatry 1998;13:368-80.

45. Solomon PR, Brush M, Calvo V, et al. Identifying dementia in the primary care practice. Int Psychogeriatr 2000;12:483-93.

46. Pfeiffer E. A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. J Am Geriatr Soc 1975;23:433-41.

47. Callahan CM, Hendrie HC, Tierney WM. Documentation and evaluation of cognitive impairment in elderly primary care patients. Ann Intern Med 1995;122:422-9.

48. Schulman K. Clock-drawing: is it the ideal cognitive screening test? Int J Geriatr Psychiatry 2000;15:548-61.

49. Kirby M, Denihan A, Bruce I, Coakley D, Lawlor BA. The clock drawing test in primary care: sensitivity in dementia detection and specificity against normal and depressed elderly. Int J Geriatr Psychiatry 2001;16:935-40.

50. Scanlan JM, Brush M, Quijano C, Borson S. Comparing clock tests for dementia screening: naíve judgments vs formal systems—what is optimal? Int J Geriatr Psychiatry 2002;17:14-21.

51. Schramm U, Berger G, Muller R, Kratzsch T, Peters J, Frolich L. Psychometric properties of Clock Drawing Test and MMSE or Short Performance Test (SKT) in dementia screening in a memory clinic population. Int J Geriatr Psychiatry 2002;17:254-60.

52. Powlishta KK, Von Dras DD, Stanford A, et al. The clock drawing test is a poor screen for very mild dementia. Neurology 2002;59:898-903.

53. Teng EL, Chui HC. The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry 1987;48:314-18.

54. Scanlan J, Borson S. The Mini-Cog: receiver operating characteristics with expert and naive raters. Int J Geriatr Psychiatry 2001;16:216-22.

55. Frank RM, Byrne GJ. The clinical utility of the Hopkins Verbal Learning Test as a screening test for mild dementia. Int J Geriatr Psychiatry 2000;15:317-24.

56. Hogervorst E, Combrinck M, Lapuerta P, Rue J, Swales K, Budge M. The Hopkins Verbal Learning Test and screening for dementia. Dement Geriatr Cogn Disord 2002;13:13-20.

57. Jarvenpaa T, Rinne JO, Raiha I, et al. Characteristics of two telephone screens for cognitive impairment. Dement Geriatr Cogn Disord 2002;13:149-55.

58. Lawrence J, Davidoff D, Katt-Lloyd D, Auerbach M, Hennen J. A pilot program of improved methods for community-based screening for dementia. Am J Geriatric Psychiatry 2001;9:205-11.

59. Mundt JC, Ferber KL, Rizzo M, Greist JH. Computer-automated dementia screening using a touch-tone telephone. Arch Intern Med 2001;161:2481-7.

60. Belle SH, Seaberg EC, Ganguli M, Ratcliff G, DeKosky S, Kuller LH. Effect of education and gender adjustment on the sensitivity and specificity of a cognitive screening battery for dementia: results from the MoVIES Project. Monongahela Valley Independent Elders Survey. Neuroepidemiology 1996;15:321-9.

61. Uhlmann RF, Larson EB. Effect of education on the Mini-Mental State Examination as a screening test for dementia. J Am Geriatr Soc 1991;39:876-80.

62. Fratiglioni L, Jorm AF, Grut M, et al. Predicting dementia from the Mini-Mental State Examination in an elderly population: the role of education. J Clin Epidemiol 1993;46:281-7.

63. Freidl W, Schmidt R, Stronegger WJ, Irmler A, Reinhart B, Koch M. Mini mental state examination: influence of sociodemographic, environmental and behavioral factors and vascular risk factors. J Clin Epidemiol 1996;49:73-8.

64. Crum RM, Anthony JC, Bassett SS, Folstein MF. Population-based norms for the Mini-Mental State Examination by age and educational level. JAMA 1993;269:2386-91.

65. National Institute on Aging/Alzheimer's Association Working Group. Apolipoprotein E genotyping in Alzheimer's disease. Lancet 1996;347:1091-5.

66. Demers L, Oremus M, Perrault A, Wolfson C. Review of outcome measurement instruments in Alzheimer's disease drug trials: introduction. J Geriatr Psychiatry Neurol 2000;13:161-69.

67. Stern R, Mohs R, Davidson M, Schmeidler J, Silverman J, Kramer-Ginsberg E et al. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry 1994;151:390-96.

68. Kramer-Ginsberg E, Mohs RC, Aryan M, et al. Clinical predictors of course for Alzheimer patients in a longitudinal study: a preliminary report. Psychopharmacol Bull 1988;24:458-62.

69. Brooks JO 3rd, Yesavage JA, Taylor J, et al. Cognitive decline in Alzheimer's disease: elaborating on the nature of the longitudinal factor structure of the Mini-Mental State Examination. Int Psychogeriatr 1993;5:135-46.

70. Salmon DP, Thal LJ, Butters N, Heindel WC. Longitudinal evaluation of dementia of the Alzheimer type: a comparison of 3 standardized mental status examinations. Neurology 1990;40:1225-30.

71. Food and Drug Administration. Peripheral and central nervous system drugs advisory committee meeting. Rockville, MD, Dept. of Health and Human Services, Public Health Service, 1989: document number 227.

72. Birks J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer's disease (Cochrane Review). Cochrane Database Syst Rev 2000;CD001191.

73. Birks J, Melzer D, Beppu H. Donepezil for mild and moderate Alzheimer's disease (Cochrane Review). Cochrane Database Syst Rev 2000;CD001190.

74. Qizilbash N, Whitehead A, Higgins J, Wilcock G, Schneider L, Farlow M. Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' Collaboration. JAMA 1998;280:1777-82.

75. Olin J, Schneider L. Galantamine for Alzheimer's disease. Cochrane Database Syst Rev 2002;CD001747.

76. Greenberg S, Tennis M, Brown L, Gomez-Isla T, Hayden D, Schoenfeld D et al. Donepezil therapy in clinical practice: a randomized crossover study. Arch Neurol 2000;57:94-99.

77. Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer's disease—results from a multinational trial. Dement Geriatr Cogn Disord 1999;10:237-44.

78. Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999;318:633-38.

79. Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001;57:481-88.

80. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001;57:489-95.

81. Petracca G, Teson A, Chemerinski E, Leiguarda R, Starkstein S. A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease. J Neuropsychiatry Clin Neurosci 1996;8:270-75.

82. Auchus A, Bissey-Black C. Pilot study of haloperidol, fluoxetine, and placebo for agitation in Alzheimer's disease. J Neuropsychiatry Clin Neurosci 1997;9:591-93.

83. Devanand D, Marder K, Michaels K, et al. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. Am J Psychiatry 1998;155:1512-20.

84. Lyketsos CG , Sheppard JM, Steele CD, et al. Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: initial results from the Depression in Alzheimer's Disease study. Am J Psychiatry 2000;157:1686-89.

85. Teri L, Logsdon RG, Peskind E, Raskind M, Weiner MF, Tractenberg RE et al. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology 2000;55:1271-78.

86. Oken B, Storzbach D, Kaye J. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol 1998;55:1409-15.

87. Birks J, Flicker L. Selegiline for Alzheimer's disease (Cochrane Review). Cochrane Database Syst Rev 2000;CD000442.

88. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997;336:1216-22.

89. Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA 2000;283:1007-15.

90. Asthana S, Baker LD, Craft S, et al. High-dose estradiol improves cognition for women with AD: results of a randomized study. Neurology 2001;57:605-12.

91. Roman GC. Vascular dementia revisited: diagnosis, pathogenesis, treatment, and prevention. Med Clin North Am 2002;86:477-99.

92. Pantoni L, Rossi R, Inzitari D, et al. Efficacy and safety of nimodipine in subcortical vascular dementia: a subgroup analysis of the Scandinavian Multi-Infarct Dementia Trial. J Neurol Sci 2000;175:124-34.

93. Williams P, Rands G, Orrel M, Spector A. Aspirin for vascular dementia. Cochrane Database Syst Rev 2000;CD001296.

94. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002;359:1283-90.

95. Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA 2002;288:1475-83.

96. Thompson C, Briggs M. Support for careers of people with Alzheimer's type dementia (Cochrane Review). Cochrane Database Syst Rev 2000.

97. Hebert R, Leclerc G, Bravo G, Girouard D, Lefrancois R. Efficacy of a support group programme for caregivers of demented patients in the community: a randomized controlled trial. Arch Gerontol Geriatr 1994;18:1-14.

98. Tappen RM. The effect of skill training on functional abilities of nursing home residents with dementia. Res Nurs Health 1994;17:159-65.

99. Hebert R, Girouard D, Leclerc G, Bravo G, Lefrancois R. The impact of a support group programme for care-givers on the institutionalization of demented patients. Arch Gerontol Geriatr 1995;20:129-34.

100. Mittelman MS, Ferris SH, Shulman E, Steinberg G, Levin B. A family intervention to delay nursing home placement of patients with Alzheimer disease. A randomized controlled trial. JAMA 1996;276:1725-31.

101. McCurry SM, Logsdon RG, Vitiello MV, Teri L. Successful behavioral treatment for reported sleep problems in elderly caregivers of dementia patients: a controlled study. J Gerontol B Psychol Sci Soc Sci 1998;53:P122-9.

102. Marriott A, Donaldson C, Tarrier N, Burns A. Effectiveness of cognitive-behavioural family intervention in reducing the burden of care in carers of patients with Alzheimer's disease. Br J Psychiatry 2000;176:557-62.

103. Mittelman MS, Ferris SH, Steinberg G, et al. An intervention that delays institutionalization of Alzheimer's disease patients: treatment of spouse-caregivers. Gerontologist 1993;33:730-40.

104. Brodaty H, Gresham M, Luscombe G. The Prince Henry Hospital dementia caregivers' training programme. Int J Geriatr Psychiatry 1997;12:183-92.

105. Morris J, Storandt M, Miller J, et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 2001;58:397-405.

106. Drickamer MA, Lachs MS. Should patients with Alzheimer's disease be told their diagnosis? N Engl J Med 1992;326:947-51.

107. Jha A, Tabet N, Orrell M. To tell or not to tell-comparison of older patients' reaction to their diagnosis of dementia and depression. Int J Geriatr Psychiatry 2001;16:879-85.

108. Barberger-Gateau P, Fabrigoule C, Helmer C, Rouch I, Dartigues J. Functional impairment in instrumental activities of daily living: an early clinical sign of dementia? J Am Geriatr Soc 1999;47:456-62.

109. Heun R. Validity of family history diagnosis for dementia. Genet Epidemiol 1999;17:151-4.

110. Lanctot K, Best T, Mittmann N, et al. Efficacy and safety of neuroleptics in behavioral disorders associated with dementia. J Clin Psychiatry 1998;59:550-61.

111. Davidson M, Weiser M, Soares K. Novel antipsychotics in the treatment of psychosis and aggression associated with dementia: A meta-analysis of randomized controlled clinical trials. Int Psychogeriatr 2000;12(Suppl 11):271-77.

112. Qizilbash N, Birks J, Lopez A, Lewington S, Szeto S. Tacrine for Alzheimer's disease. [update of: 20257597] (Cochrane Review). Cochrane Database Syst Rev 2000;CD000202.

113. Kirchner V, Kelly C, Harvey R. Thioridazine for dementia (Cochrane Review). Cochrane Database Syst Rev 2000;CD000464.

114. Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer's disease. I: Disorders of thought content. Br J Psychiatry 1990;157:72-76, 92-94.

115. Maurer K, Ihl R, Dierks T, Frolich L. Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type. J Psychiatr Res 1997;31:645-55.

116. Le Bars P, Katz M, Berman N, Itil T, Freedman A, Schatzberg A. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA 1997;278:1327-32.

117. Aisen P, Davis K, Berg J, et al. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology 2000;54:588-93.

118. Scharf S, Mander A, Ugoni A, Vajda F, Christophidis N. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 1999;53:197-201.

119. McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000;356:2031-36.

Return to Contents

Notes

Author Affiliations

[a] Boustani: Indiana University Center for Aging Research, Indiana University School of Medicine, Indianapolis, IN.
[b] Peterson: Department of Psychiatry, University of New Mexico School of Medicine Albuquerque, NM.
[c] Hanson: Program on Aging, University of North Carolina School of Medicine, Chapel Hill, NC.
[d] Harris: Cecil G. Sheps Center for Health Services Research, University of North Carolina School of Medicine, Chapel Hill, NC.
[e] Lohr: Department of Health Policy and Administration, School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, and RTI International, Research Triangle Park, NC.

Copyright and Source Information

This document is in the public domain within the United States. For information on reprinting, contact Randie Siegel, Director, Division of Printing and Electronic Publishing, Agency for Healthcare Research and Quality, Suite 501, 2101 East Jefferson Street, Rockville, MD 20852. Requests for linking or to incorporate content in electronic resources should be sent to info@ahrq.gov.

Source: Boustani M, Peterson B, Hanson L, Harris R, Lohr K. Screening for Dementia in Primary Care: A summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2003;138: 927-37.

Return to Contents

Current as of June 2003

Internet Citation:

Boustani M, Peterson B, Hanson L, Harris R, Lohr K. Screening for Dementia in Primary Care: A summary of the evidence for the U.S. Preventive Services Task Force. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/clinic/3rduspstf/dementia/dementsum.htm